Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million

On June 15, 2022 Scandion Oncology (Scandion or "The Company"), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported a prospectus in connection with the rights issue of shares (the "Rights Issue") announced on June 1, 2022, for which the subscription period commences on June 16, 2022 (Press release, Scandion Oncology, JUN 15, 2022, View Source,c3585777 [SID1234615991]). The prospectus has today been approved and registered by the Danish Financial Supervisory Authority (Finanstilsynet).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of the Rights Issue

For one (1) existing share on the record date of June 13 2022, shareholders will receive one (1) subscription right, three (3) subscription rights entitle to subscription of one (1) share.
The subscription price is SEK 8.75 per new share, which, assuming the Rights Issue is fully subscribed, results in the Company receiving issue proceeds of approximately SEK 93.7 million before deduction of transaction costs.
Subscription and guarantee commitments have been received from principal owners and new investors amounting to approximately SEK 75 million, corresponding to approximately 80% of the issue proceeds.
For complete information on the Rights Issue, please see the published prospectus.

Prospectus

The prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on June 15 2022, been approved and registered by the Danish Financial Supervisory Authority. The prospectus, including full terms and conditions, is available on the Company’s, Hagberg & Aneborn Fondkommission AB’s and Redeye’s respective websites (www.scandiononcology.com, www.hagberganeborn.se, www.redeye.se). The Swedish Financial Supervisory Authority (Finansinspektionen) will issue a certificate of European passport today, on June 15 2022. A summary of the prospectus in Swedish will be available on the above websites when the certificate is issued. Application forms for subscription without preferential rights will be available on the above websites as the subscription period commences.

Timetable for the Rights Issue

The record date for participating in the Rights Issue was June 13 2022. The last day of trading including the right to subscribe for shares was June 9. The first day of trading excluding the right to subscribe for shares was June 10 2022.

June 16 – June 28, 2022 Trading in subscription rights
June 16 – July 1, 2022 Subscription period
June 16 – until registration with the Danish Business Authority Trading in paid subscription shares (Sw. "BTA")
July 5, 2022 Estimated announcement of outcome in the Rights Issue
Advisers

Redeye AB acts as financial adviser and Horten Advokatpartnerselskab (as to Danish law) and Advokatfirman Schjødt (as to Swedish law) acts as legal advisers in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.